Kiora Pharmaceuticals (KPRX)
NASDAQ:KPRX
Want to see KPRX full AI Analyst Report?
Top Page
Kiora Pharmaceuticals
(NASDAQ:KPRX)
Select Model
Select Model
Rating:50Neutral
Price Target:
$2.50
▲(30.89% Upside)
Action:Reiterated
Date:06/18/26
The score is held back primarily by weak financial performance (zero revenue, sizeable losses, and continued cash burn) and limited valuation support (negative P/E, no dividend). Technical indicators are mixed/neutral, while corporate events provide a modest offset through early-stage pipeline progress and added financing capacity.
Positive Factors
Low leverage / limited debt
Very low debt-to-equity (~0.03) materially reduces solvency and interest-rate pressure, giving the company financial flexibility to prioritize R&D and trial execution. This durable capital structure lowers default risk and preserves optionality while cash burn continues.
Negative Factors
Zero revenue and sustained cash burn
The absence of revenue and persistent negative operating and free cash flow (~$10M+ TTM) mean the business relies on external funding to sustain clinical programs. This structural cash burn raises execution and financing risk over the coming months absent durable revenue or large financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / limited debt
Very low debt-to-equity (~0.03) materially reduces solvency and interest-rate pressure, giving the company financial flexibility to prioritize R&D and trial execution. This durable capital structure lowers default risk and preserves optionality while cash burn continues.
Read all positive factors
Kiora Pharmaceuticals (KPRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.21M
Dividend YieldN/A
Average Volume (3M)36.18K
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue Growth-100.00%
EPS Growth13.00%
CountryUS
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.66
Shares Outstanding4,431,940
10 Day Avg. Volume38,148
30 Day Avg. Volume36,176
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.51
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap0.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-19.26
Enterprise Value/Ebitda-0.07
Forecast
1Y Price Target
$12.00Price Target Upside528.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.89
Revenue Forecast (FY)$1.50M
Kiora Pharmaceuticals Business Overview & Revenue Model
Company Description
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic can...
How the Company Makes Money
null...
Kiora Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 16.00M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -41.98K | -24.80K | 16.00M | 0.00 | 0.00 | 0.00 |
| EBITDA | -12.39M | -12.07M | 5.70M | -12.36M | -13.65M | -13.91M |
| Net Income | -11.06M | -10.84M | 3.59M | -12.51M | -13.58M | -13.77M |
Balance Sheet | ||||||
| Total Assets | 21.23M | 24.25M | 36.48M | 13.71M | 18.68M | 20.13M |
| Cash, Cash Equivalents and Short-Term Investments | 13.87M | 17.09M | 26.79M | 2.45M | 5.96M | 7.85M |
| Total Debt | 373.59K | 368.26K | 57.17K | 106.89K | 105.78K | 209.41K |
| Total Liabilities | 7.29M | 8.13M | 10.72M | 7.60M | 7.27M | 5.55M |
| Stockholders Equity | 13.93M | 16.13M | 25.76M | 6.11M | 11.41M | 14.58M |
Cash Flow | ||||||
| Free Cash Flow | -10.53M | -10.07M | 8.55M | -9.56M | -10.43M | -10.74M |
| Operating Cash Flow | -10.42M | -9.96M | 8.56M | -9.56M | -10.43M | -10.68M |
| Investing Cash Flow | 17.15M | 14.43M | -22.66M | 0.00 | 6.38K | -157.02K |
| Financing Cash Flow | 264.81K | 265.65K | 15.50M | 5.97M | 8.62M | 17.58M |
Kiora Pharmaceuticals Technical Analysis
Neutral
1.91
Price Trends
2.54
Positive
2.31
Positive
2.33
Positive
Market Momentum
0.01
Positive
49.69
Neutral
40.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KPRX, the sentiment is Neutral. The current price of 1.91 is below the 20-day moving average (MA) of 2.64, below the 50-day MA of 2.54, and below the 200-day MA of 2.33, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 49.69 is Neutral, neither overbought nor oversold. The STOCH value of 40.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KPRX.
Kiora Pharmaceuticals Risk Analysis
Kiora Pharmaceuticals disclosed 50 risk factors in its most recent earnings report. Kiora Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Kiora Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $11.21M | -0.95 | -32.58% | ― | -100.00% | 13.00% | |
49 Neutral | $4.47M | -0.11 | -684.86% | ― | ― | 95.40% | |
44 Neutral | $52.13M | -1.84 | -35.91% | ― | ― | 40.89% | |
44 Neutral | $17.45M | -0.10 | -83.59% | ― | ― | 19.36% | |
41 Neutral | $17.57M | -0.13 | 0.02% | ― | ― | -101.45% |
* Healthcare Sector Average
KPRX
Kiora Pharmaceuticals
2.53
-0.67
-20.94%
GNPX
Genprex
0.59
-12.61
-95.52%
DWTX
Dogwood Therapeutics
1.55
-3.35
-68.37%
SNSE
Sensei Biotherapeutics
13.85
6.19
80.81%
RNAZ
TransCode Therapeutics
4.70
-2.87
-37.91%
AEON
AEON Biopharma
0.67
-0.07
-9.73%
Kiora Pharmaceuticals Corporate Events
Business Operations and StrategyProduct-Related Announcements
Kiora Showcases Promising Preclinical Epilepsy Data for KIO-300
Positive
Jun 18, 2026
On June 18, 2026, Kiora Pharmaceuticals reported preclinical data showing that its ion channel modulator KIO-300 significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy model. The data, presen...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Kiora Pharmaceuticals Shareholders Approve Expanded Equity Incentive Plan
Positive
Jun 11, 2026
On June 10, 2026, Kiora Pharmaceuticals, Inc. held its 2026 annual meeting of stockholders, where shareholders approved an amendment to the 2024 Equity Incentive Plan to add 1,500,000 shares of common stock for potential issuance. The meeting also...
Business Operations and StrategyPrivate Placements and Financing
Kiora Pharmaceuticals Announces $5 Million Private Placement Financing
Positive
Apr 7, 2026
On April 3, 2026, Kiora Pharmaceuticals entered into a securities purchase agreement with institutional investors Perceptive Advisors and ADAR1 Capital Management for a private placement of common stock, pre-funded warrants, and milestone-based co...
Business Operations and StrategyExecutive/Board Changes
Kiora Pharmaceuticals Announces Chief Development Officer Resignation
Neutral
Apr 2, 2026
On April 1, 2026, Kiora Pharmaceuticals announced that Chief Development Officer Eric J. Daniels, M.D., MBA, had submitted his resignation, effective April 17, 2026, to pursue another opportunity. The company said his departure, disclosed publicly...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.